ArticleRespiratory research2023
Dysbiosis of the intestinal fungal microbiota increases lung resident group 2 innate lymphoid cells and is associated with enhanced asthma severity in mice and humans.
Article in Respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 37 citations in OpenAlex.
- Antibiotic treatment for non-specific upper respiratory tract infections and exacerbation risk in children with asthma: a target trial emulation study.American journal of epidemiology · 2026Article
- Candida in the lung: Fact, fiction, friend or foe?PLoS pathogens · 2026Article
- Comprehensive insights into the roles of eosinophils in the mucosal immunity of gastrointestinal tract: defenders, destructors, and modulators.Frontiers in immunology · 2026Review
- From gut to lung: the microbiome-directed causal mechanisms and therapeutic horizons in asthma.Frontiers in immunology · 2026Review
- Review
- Advances in the Gut-Lung Axis and Bronchial Asthma: From Mechanisms to Therapeutic Potential.Clinical and translational allergy · 2025Review
- Interactions between the gut microbiota and immune cell dynamics: novel insights into the gut-bone axis.Gut microbes · 2025Review
- The epithelial barrier theory proposes a comprehensive explanation for the origins of allergic and other chronic noncommunicable diseases.FEBS letters · 2025Review
- The role of dietary fibre in lung inflammation: microbiota, metabolites, and immune crosstalk.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Intestinal fungi biogeography, succession and its association with diarrhea in pigs.Journal of animal science and biotechnology · 2025Article
- Gut Mycobiome: Latest Findings and Current Knowledge Regarding Its Significance in Human Health and Disease.Journal of fungi (Basel, Switzerland) · 2025Review
- Article
- Review
- The Microbiome in Asthma Heterogeneity: The Role of Multi-Omic Investigations.Immunological reviews · 2025Review
- Type 2 immunity in allergic diseases.Cellular & molecular immunology · 2025Review
- Harnessing the Farm Effect: Microbial Products for the Treatment and Prevention of Asthma Throughout Life.Immunological reviews · 2025Review
- Gut mycobiota dysbiosis and an emergent state of "co-dysbiosis" are associated with IgE sensitization in children with comorbid allergic rhinitis and constipation.Frontiers in immunology · 2025Article
- Respiratory diseases and the gut microbiota: an updated review.Frontiers in cellular and infection microbiology · 2025Review
- Maternal antibiotic exposure-mediated alterations in basal, and allergen-induced lung function are associated with altered recruitment of eosinophils to the developing lung.Frontiers in immunology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe gut-lung axis is the concept that alterations of gut microbiota communities can influence immune function in the lungs. While studies have explored the relationship between intestinal bacterial dysbiosis and asthma development, less is understood about the impact of commensal intestinal fungi on asthma severity and control and underlying mechanisms by which this occurs.
methodsWild-type mice were treated with Cefoperazone to deplete gut bacteria and administered Candida albicans or water through gavage. Mice were then sensitized to house dust mite (HDM) and their lungs were analyzed for changes in immune response. Humans with asthma were recruited and stool samples were analyzed for Candida abundance and associations with asthma severity and control.
resultsMice with intestinal Candida dysbiosis had enhanced Th2 response after airway sensitization with HDM, manifesting with greater total white cell and eosinophil counts in the airway, and total IgE concentrations in the serum. Group 2 innate lymphoid cells (ILC2) were more abundant in the lungs of mice with Candida gut dysbiosis, even when not sensitized to HDM, suggesting that ILC2 may be important mediators of the enhanced Th2 response. These effects occurred with no detectable increased Candida in the lung by culture or rtPCR suggesting gut-lung axis interactions were responsible. In humans with asthma, enhanced intestinal Candida burden was associated with the risk of severe asthma exacerbation in the past year, independent of systemic antibiotic and glucocorticoid use.
conclusionsCandida gut dysbiosis may worsen asthma control and enhance allergic airway inflammation, potentially mediated by ILC2. Further studies are necessary to examine whether microbial dysbiosis can drive difficult-to-control asthma in humans and to better understand the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.